NCT00453089Unknown1 期
A Phase I/II Dose Escalation Clinical Trial to Assess Safety and Efficacy of VG101 to Treat the Symptoms of Vulvar and Vaginal Atrophy in Post-Menopausal Women
Bionovo4 个研究点 分布在 1 个国家目标入组 40 人开始时间: 2012年6月1日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 发起方
- 入组人数
- 40
- 试验地点
- 4
- 主要终点
- Change in self-reported symptoms of vaginal atrophy from baseline to 12 weeks
研究概览
简要总结
To conduct a prospective, randomized, blinded, placebo controlled, dose escalation clinical trial in 4 cohorts of 10 postmenopausal women (total N=40) aged 45 to 65 years with at least one menopausal vaginal symptom, vaginal pH > 5.0 and > 20% parabasal vaginal epithelial cells.
详细描述
Primary Aims:
- the optimal dose of VG101 based on the highest of 4 proposed dose levels that is not associated with unacceptable toxicity during 12 weeks of treatment. Toxicity will be based on National Cancer Institute (NCI) Common Toxicity Criteria for Adverse Events (CTCAE), version 3. Unacceptable toxicity will be defined as the occurrence of any Grade 3, 4, of 5 toxicity that is possibly or probably associated with study drug or any other unacceptable toxicity as determined by the Data and Safety Monitoring Board.
- Specific potential adverse effects of VG101
Secondary Aims:
- the preliminary efficacy of VG101 to:
- relieve vulvar and/or vaginal dryness,
- relieve vulvar and/or vaginal irritation
- relieve vulvar and/or vaginal itching
- relieve vulvar and/or vaginal discharge
- relieve dyspareunia
- improve sexual function
- relieve dysuria
- reduce frequency of urinary incontinence
- improve quality of life
- improve the physical examination assessment of vaginal atrophy
- reduce vaginal fluid pH
- improve the proportion of superficial vaginal epithelial cells
- participant adherence to VG101 administration
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 45 Years 至 65 Years（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 是
入选标准
- •Women between the ages of 45 and 65
- •Postmenopausal documented by: (a) at least one year of amenorrhea; (b) 6- 12 months of amenorrhea with serum FSH > 40 IU/ml; (c) 6 weeks post-surgical bilateral oophorectomy with or without hysterectomy, or (d) hysterectomy with serum FSH levels > 40 IU/ml.
- •Self-report at least one moderate to severe symptom of vulvar or vaginal atrophy from the following list:
- •Vaginal dryness (none, mild, moderate or severe)
- •Vaginal and/or vulvar discomfort (none, mild, moderate, severe)
- •Vaginal and/or vulvar irritation (none, mild, moderate, severe)
- •Vaginal itching (none, mild, moderate, severe)
- •Vaginal pain associated with sexual activity (none, mild, moderate or severe)
- •< 5% superficial cells on vaginal cytologic smear.
- •Vaginal pH >5.0
- •Willing to use an intravaginal cream containing Chinese herbs for the treatment of vaginal symptoms.
- •Provide informed consent.
排除标准
- •History of breast, uterine or ovarian cancer or melanoma.
- •Abnormal mammogram or breast examination within the last 9 months suggestive of cancer.
- •Abnormal Pap smear or pelvic examination within the last 9 months suggestive of cancer.
- •Any uterine or vaginal bleeding within the six months prior to enrollment (except following the screening Pap smear).
- •Double-wall endometrial thickness that exceeds 5 mm measured on transvaginal ultrasound.
- •Pregnant or lactating.
- •Use of any vaginal moisturizer (Replens, KY Silk-E, Astroglide Silken Secret, Senselle) within 30 days of screening.
- •Use of any oral, transdermal, vaginal, or systemic estrogen or estrogen/progestin product within 30 days of screening.
- •Use of raloxifene, tamoxifen or aromatase inhibitors within 12 weeks of screening.
- •Current urinary tract infection (dipstick urinalysis positive for leukocyte estrace, nitrates or blood)
- •History of cardiovascular disease.
- •History of venous thromboembolic disease.
- •Use of another investigational agent within 12 weeks of screening.
- •Any medical or psychiatric condition that, in the investigator's opinion, would preclude the participant from completing questionnaires or measures, adhering to the protocol or completing the trial, including limited English literacy, severe illness, plans to move, substance abuse, significant psychiatric problems, or dementia.
- •No access to a telephone
结局指标
主要结局
Change in self-reported symptoms of vaginal atrophy from baseline to 12 weeks
时间窗: 4 and 12 weeks
Change in percent superficial vaginal epithelial cells from baseline 12 weeks
时间窗: 4 and 12 weeks
Change in the pH of vaginal secretions from baseline to 12 weeks
时间窗: 4 and 12 weeks
次要结局
未报告次要终点
研究者
研究点 (4)
Loading locations...
相似试验
已完成
1 期
A Study to Evaluate the Safety and Efficacy of DDO-3055 in Healthy Volunteers and Patients With Chronic Kidney DiseaseChronic Kidney DiseaseNCT03976115Jiangsu HengRui Medicine Co., Ltd.54
招募中
1 期
A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacokinetic of TQB3702 Tablets in Healthy Adult SubjectsSystemic Lupus ErythematosusNCT06448273Chia Tai Tianqing Pharmaceutical Group Co., Ltd.40
已完成
1 期
Study to Evaluate Safety, Tolerability and Explorative Efficacy of DM-101PX in Birch Pollen Allergic ParticipantsBirch Pollen AllergyNCT06037148Desentum Oy30
已完成
1 期
A Study of IBI311 in Healthy VolunteersHealthyNCT05480579Innovent Biologics (Suzhou) Co. Ltd.28
进行中（未招募）
1 期
A Clinical Trial to Evaluate the Safety and Immunogenicity of rVSV∆G-LASV-GPC Vaccine in Adults in Good General HeathLassa Virus InfectionLassa FeverNCT04794218International AIDS Vaccine Initiative114